| Released | Contributor | Author | Title | Pages | Price |
| 29-Nov-2009 | Wright Reports |
N/A
| Wright Investors Service Comprehensive Report for Ligand Pharmaceuticals Inc | 44 |
$65 |
| 28-Nov-2009 | Standard & Poor's Quantitative Report |
N/A
| Ligand Pharmaceuticals 'B' | 5 |
$25 |
| 27-Nov-2009 | Pechala's Reports | Frantisek Pechala | LIGAND PHARMACEUTICALS INC CL B (LGND=US) 12-months forecast | 1 |
$15 |
| 27-Nov-2009 | Pechala's Reports | Lubomir Pechala | LIGAND PHARMACEUTICALS INC CL B (LGND=US) 2-weeks forecast | 1 |
$10 |
| 26-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for DRUGS | 18 |
$49 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: ALKS , HITK , LGND , PANC , PPCO , UTHR -- DRUGS | 3 |
$4 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Value Graph: LIGAND PHARMACEU -- LGND | 1 |
$4 |
| 26-Nov-2009 | New Constructs, LLC |
N/A
| LGND: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings | 19 |
$10 |
| 26-Nov-2009 | Pechala's Reports | Lubomir Pechala | LIGAND PHARMACEUTICALS INCORPORATED (LGND=US) - REPORT FOR ACTIVE TRADERS | 4 |
$25 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotechnology & Genetics Industry Market Research and Competitive Analysis 2010 | 569 |
$299 |
1.48% Nasdaq 0.00%
Research Reports
